| Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project M D'agostino, DA Cairns, JJ Lahuerta, R Wester, U Bertsch, A Waage, ... Journal of clinical oncology 40 (29), 3406-3418, 2022 | 171 | 2022 |
| Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma A Larocca, F Bonello, G Gaidano, M D’Agostino, M Offidani, N Cascavilla, ... Blood, The Journal of the American Society of Hematology 137 (22), 3027-3036, 2021 | 54 | 2021 |
| CD38 as an immunotherapeutic target in multiple myeloma F Bonello, M D’Agostino, M Moscvin, C Cerrato, M Boccadoro, F Gay Expert opinion on biological therapy 18 (12), 1209-1221, 2018 | 45 | 2018 |
| Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma F Bonello, R Mina, M Boccadoro, F Gay Cancers 12 (1), 15, 2019 | 43 | 2019 |
| Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era begins V Magarotto, M Salvini, F Bonello, S Bringhen, A Palumbo Leukemia & lymphoma 57 (3), 537-556, 2016 | 23 | 2016 |
| Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies R Mina, F Bonello, MT Petrucci, AM Liberati, C Conticello, S Ballanti, ... haematologica 106 (4), 1079, 2021 | 19 | 2021 |
| Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients F Bonello, M Boccadoro, A Larocca Cancers 12 (11), 3106, 2020 | 14 | 2020 |
| How is patient care for multiple myeloma advancing? S Genadieva Stavric, F Bonello, S Bringhen, M Boccadoro, A Larocca Expert review of hematology 10 (6), 551-561, 2017 | 14 | 2017 |
| Risk stratification before and during treatment in newly diagnosed multiple myeloma: from clinical trials to the real-world setting F Bonello, L Cani, M D’Agostino Frontiers in Oncology 12, 830922, 2022 | 12 | 2022 |
| Determining treatment intensity in elderly patients with multiple myeloma M Salvini, M D’Agostino, F Bonello, M Boccadoro, S Bringhen Expert review of anticancer therapy 18 (9), 917-930, 2018 | 12 | 2018 |
| A multicenter, open label phase I/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (MM) patients S Bringhen, V Magarotto, AM Liberati, A Belotti, A Larocca, M Gilestro, ... Blood 128 (22), 1145, 2016 | 12 | 2016 |
| Safety of rapid daratumumab infusion: a retrospective, multicenter, real-life analysis on 134 patients with multiple myeloma F Bonello, S Rocchi, G Barilà, M Sandrone, M Talarico, E Zamagni, ... Frontiers in oncology 12, 851864, 2022 | 10 | 2022 |
| The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma F Bonello, M Grasso, M D’Agostino, I Celeghini, A Castellino, ... Pharmaceuticals 14 (1), 20, 2020 | 10 | 2020 |
| Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: a pooled analysis F Bonello, S Pulini, S Ballanti, M Gentile, S Spada, O Annibali, P Omedé, ... Cancers 11 (11), 1735, 2019 | 9 | 2019 |
| Minimal residual disease in multiple myeloma: ready for prime time? R Mina, F Bonello, S Oliva The Cancer Journal 27 (3), 247-255, 2021 | 8 | 2021 |
| Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial R Mina, AP Falcone, S Bringhen, AM Liberati, N Pescosta, MT Petrucci, ... Blood Cancer Journal 11 (12), 197, 2021 | 6 | 2021 |
| Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age> 80 in the IMWG frailty score M D’Agostino, A Larocca, M Offidani, AM Liberati, G Gaidano, MT Petrucci, ... Blood Cancer Journal 11 (4), 73, 2021 | 6 | 2021 |
| Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in transplant-ineligible real-life multiple myeloma patients: Updated results of the randomized phase … S Bringhen, M D'Agostino, N Giuliani, I Attucci, R Zambello, S Ronconi, ... Blood 140 (Supplement 1), 1814-1816, 2022 | 4 | 2022 |
| On-demand plerixafor with cyclophosphamide and G-CSF for hematopoietic stem-cell mobilization in multiple myeloma patients: preliminary results of a prospective observational … R Mina, F Bonello, G Milone, MT Petrucci, C Nozzoli, V Bongarzoni, ... Blood 136, 13-14, 2020 | 4 | 2020 |
| New drugs in early development for treating multiple myeloma: all that glitters is not gold L Bertamini, F Bonello, M Boccadoro, S Bringhen Expert Opinion on Investigational Drugs 29 (9), 989-1004, 2020 | 4 | 2020 |
